Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model

Date

12 Dec 2024

Session

Poster Display session

Presenters

Rui Coelho

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-6. 10.1016/iotech/iotech100743

Authors

R. Coelho1, C. Schliehe1, E. Shifrut2, R. Debets1, D. Hammerl3

Author affiliations

  • 1 Erasmus MC, Rotterdam/NL
  • 2 Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL
  • 3 Pan Cancer T, Rotterdam/NL

Resources

This content is available to ESMO members and event participants.

Abstract 64P

Background

Tumor associated macrophages (TAMs) are highly abundant immune cells present within the microenvironment of multiple tumor types. TAMs with a type 2 (M2)-like phenotype generally associate with poor prognosis and resistance against immunotherapy. In fact, we observed high frequencies of M2-like TAMs relative to those of CD8+ T cells according to gene expression analyses in multiple tumor types. In this study, we aim to engineer CD8+ T cells that resist M2-like macrophage-mediated suppression.

Methods

First, we have set up an in vitro co-culture model of human autologous M2-like macrophages and CD8+ T cells that yields T cell suppression. To this end, we have polarized in vitro monocytes from healthy donors into M2-like macrophages using a cytokine cocktail, after which we have optimized critical parameters, such as type of T cell stimulation, co-culture duration and the ratio between the two cell types.

Results

With this model, we have demonstrated that M2-like macrophages from multiple donors, when co-cultured with anti-CD3/CD28 antibody-stimulated autologous CD8+ T cells for 6 days, suppressed T cell proliferation by 50%. In a second step, we have adapted this model to a CRISPR-Cas9 gene editing-based approach: single guide RNA lentiviral infection with Cas9 electroporation (SLICE). We have successfully performed single gene editing, and are currently editing CD8+ T cells with gene libraries targeting kinases.

Conclusions

Taken together, we present a robust in vitro model of M2-like macrophage-mediated suppression of CD8+ T cells which enables the identification of genes that contribute to suppression-resistant CD8+ T cells. The making of such synthetic T cells is anticipated to aid the anti-tumor efficacy of adoptive T cell therapy.

Legal entity responsible for the study

Erasmus MC.

Funding

KWF Kankerbestrijding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.